ALK G1202R: the solvent-front mutation that lorlatinib was designed to beat

Not every resistance mutation sits deep in the pocket. Some sit at the mouth of it, where the drug is half in the protein and half in the surrounding water. G1202R in ALK is the classic example of this "solvent-front" position. Swapping a small glycine for a big, charged arginine right at that edge puts a bulky side chain exactly where second-generation ALK inhibitors stick out into solvent, and it shoulders them out of the pocket. It is one of the most common reasons ALK-positive lung cancer stops responding to alectinib and ceritinib.

What "solvent front" means

A kinase inhibitor rarely buries completely. Part of it threads into the hydrophobic interior, and part of it points back out toward the solvent-exposed rim of the ATP site. Residues on that rim are the solvent-front positions. They tolerate a lot of natural variation because they face water, not the drug's core contacts, which is precisely why a mutation there can be well tolerated by the protein but catastrophic for a drug that happens to reach into that region.

Why glycine to arginine is such a problem

Glycine has essentially no side chain, so the wild-type solvent front is open and forgiving. Arginine is one of the largest amino acids and carries a positive charge. Dropping it in at position 1202 does two things: it physically fills space the drug's solvent-exposed portion needs, and it changes the local electrostatics. Second-generation ALK inhibitors were not shaped to avoid that bulk, so they clash and lose affinity. The mutation barely bothers the kinase, which keeps signaling.

How lorlatinib gets around it

Lorlatinib, a third-generation ALK inhibitor, was designed as a compact macrocycle: its ends are tied together into a ring so the molecule is small and rigid and does not splay out into the solvent front the way earlier drugs do. Because it presents less bulk at that rim, the arginine has less to clash with, and lorlatinib retains activity against G1202R where the previous generation failed. It is a clean illustration that beating a solvent-front mutation is a shape problem: shrink or reroute the part of the molecule that reaches into the mutated region.

The catch: compound mutations

Lorlatinib is not the end of the story. Under sequential treatment, tumors can acquire compound mutations, two ALK changes on the same allele, such as G1202R paired with a second substitution. These combinations can resist even lorlatinib, and they are a motivation for the next wave of inhibitors. For anyone screening compounds, it is a reminder that a scaffold that clears one solvent- front mutation still has to be checked against the compound mutants that follow it.

Seeing the shift by docking

G1202R is a good docking case because the mechanism is steric and electrostatic at a well-defined position. Dock a second-generation ALK inhibitor into wild-type ALK and into a G1202R model, and the mutant pose degrades as the search tries to place the molecule past the bulky arginine. Dock lorlatinib into the same pair and the penalty is smaller. Comparing wild-type against mutant is a fast way to ask whether a scaffold reaches into the solvent front, and therefore whether this mutation will hurt it.

Try it on the mutation

Open Studio and dock an ALK inhibitor against wild-type and a G1202R pocket in one run. Liganx is mutation-aware molecular docking online: free and browser-based, so you can compare wild-type versus mutant binding and rank the shift to decide which compounds survive a solvent-front mutation. It is a fast first pass, not a final verdict.

Primary sources

• Shaw AT, Solomon BJ, Besse B, et al. ALK resistance mutations and efficacy of lorlatinib in advanced ALK-positive non-small-cell lung cancer. J Clin Oncol 37, 1370-1379 (2019). doi:10.1200/JCO.18.02236
• Yoda S, Lin JJ, Lawrence MS, et al. Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer. Cancer Discov 8, 714-729 (2018). doi:10.1158/2159-8290.CD-17-1256